Estudio de pembrolizumab más quimioterapia frente a placebo más quimioterapia para el cáncer de mama inoperable o metastásico localmente recurrente HR+/HER2-
The safety and efficacy of pembrolizumab plus the investigator’s choice of chemotherapy will be assessed compared to placebo plus the investigator’s choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive,